{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-125347","form_type":"8-K","ticker":"KRRO","cik":"0001703647","company_name":"Korro Bio, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.282196+00:00","generated_at":"2026-05-30T02:02:24.747681+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Korro Bio reports Q3 net loss $21M, cash $169.1M; files clinical study for KRRO-110, partners Novo Nordisk","bullets":["Net loss of $21.0M for Q3 2024 vs $18.5M in Q3 2023; R&D expenses $16.0M (up from $14.0M).","Cash and equivalents $169.1M as of Sep 30, 2024; cash runway into H2 2026.","Submitted regulatory filing in Australia for Phase 1/2 study of KRRO-110 in AATD; first dosing expected Q1 2025.","Announced collaboration with Novo Nordisk for up to two targets in cardiometabolic diseases; up to $530M in milestones plus royalties.","Appointed Jeffrey Cerio as General Counsel, Katharine Knobil to Board; formed Clinical Advisory Board."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-125347","json":"https://secwatch.observer/filing/0000950170-24-125347.json","markdown":"https://secwatch.observer/filing/0000950170-24-125347.md","text":"https://secwatch.observer/filing/0000950170-24-125347.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703647/000095017024125347/0000950170-24-125347-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703647/000095017024125347/krro-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:02:24.747681+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}